While Organon & Co has underperformed by -1.83%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, OGN rose by 30.02%, with highs and lows ranging from $23.10 to $10.84, whereas the simple moving average fell by -22.12% in the last 200 days.
On September 06, 2024, JP Morgan Downgraded Organon & Co (NYSE: OGN) to Underweight. A report published by Goldman on November 03, 2023, Downgraded its rating to ‘Neutral’ for OGN. Barclays also rated OGN shares as ‘Overweight’, setting a target price of $28 on the company’s shares in an initiating report dated September 21, 2023. Raymond James Initiated an Outperform rating on March 16, 2023, and assigned a price target of $33. BofA Securities October 14, 2022d its ‘Neutral’ rating to ‘Underperform’ for OGN, as published in its report on October 14, 2022. Piper Sandler’s report from September 06, 2022 suggests a price prediction of $34 for OGN shares, giving the stock a ‘Overweight’ rating. BofA Securities also rated the stock as ‘Neutral’.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Analysis of Organon & Co (OGN)
Investors in Organon & Co will get a return regardless of how the company performs over the next quarter since the company’s dividend stands at $1.12 per share. Further, the quarter-over-quarter increase in sales is 4.15%, showing a positive trend in the upcoming months.
One of the most important indicators of Organon & Co’s future performance is equity, which can be evaluated using several well-rounded types of analysis and research techniques. Taking into account the quick ratio of the company, currently set at 1.21, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
For any stock, average volume can also provide valuable insight into volatility, and OGN is recording 2.19M average volume. On a monthly basis, the volatility of the stock is set at 3.27%, whereas on a weekly basis, it is put at 3.01%, with a loss of -6.30% over the past seven days. Furthermore, long-term investors anticipate a median target price of $22.38, showing growth from the present price of $15.03, which can serve as yet another indication of whether OGN is worth investing in or should be passed over.
How Do You Analyze Organon & Co Shares?
The Drug Manufacturers – General market is dominated by Organon & Co (OGN) based in the USA. When comparing Organon & Co shares with other companies under Healthcare, the P/E value is an influential factor to note. This is because it represents an indication of the future growth of the company in terms of investors’ expectations. Ultimately, the value of the latter should demonstrate steady, rapid growth, which is an accurate measure of the company’s progress. In addition to the value of 2.98, there is a growth in quarterly earnings of 511.01%.
Along with the fundamentals, it is also important to consider how many employees own shares of the company. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 0.22%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 80.94% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
OGN shares are owned by institutional investors to the tune of 80.94% at present.
